A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma
This important study is for people with advanced melanoma that hasn't been treated before. We're testing a new medication called RO7198457 alongside a standard treatment, Keytruda. Our main goal is to find out if this new combination can stop the cancer from growing for longer compared to using Keytruda on its own. We'll also be looking at how well the tumours respond, how long people live, and how this treatment affects their overall quality of life. Safety is very important, so we'll carefully monitor for any side effects. This is a Phase II study, meaning we're still in the early stages of understanding how effective and safe this new combination might be.
At a glance
What is this study about?
This study is designed for individuals who have been diagnosed with advanced melanoma – a serious type of skin cancer – and haven't received treatment for it yet. The main idea behind this research is to see if a new experimental drug, called RO7198457, can work better when given together with a medicine that's already used for melanoma, called Keytruda (its active ingredient is Pembrolizumab).
Doctors want to find out if this new combination treatment can stop the cancer from getting worse for a longer period of time compared to just using Keytruda alone. They'll also be closely watching other important things, like if the tumours shrink, how long people live, and how the treatment affects day-to-day life and general well-being. Looking at these different aspects helps us understand the full impact of the treatment.
Because this is a 'Phase II' study, it means researchers are still in the relatively early stages of testing this new combination. They have some early information that suggests it might help, but they need to gather more detailed information about its effectiveness and safety in a larger group of people. The ultimate goal is to find better and safer ways to treat advanced melanoma.
Key takeaways
- This study evaluates a new drug combination for advanced, untreated melanoma.
- It compares RO7198457 plus Keytruda against Keytruda alone.
- The main goal is to see if the new combination stops cancer growth for longer.
- Researchers will also track quality of life and side effects.
- Participation involves regular hospital visits for treatments and assessments.
Who may be eligible?
To join this study, people need to be at least 18 years old. There's no upper age limit, meaning older adults can also take part. Both men and women are welcome to participate.
Because this study is specifically looking at advanced melanoma that hasn't been treated yet, your doctors will need to confirm that your cancer fits this description. You would also need to be well enough generally to take part in a clinical trial.
There will be other detailed medical checks to make sure the study is a safe and appropriate option for you. Your study doctor and nurse will discuss all these requirements with you in full detail.
- Are you at least 18 years old?
- Have you been diagnosed with advanced melanoma?
- Have you not received any prior treatment for your advanced melanoma?
- Are you generally well enough to participate in a clinical trial?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part, you'll be randomly assigned to receive either the new drug RO7198457 plus Keytruda, or Keytruda on its own. This is done by chance, like flipping a coin, and neither you nor the doctors can choose which group you're in. You'll receive your study medications through an infusion (a drip into your arm) at the hospital.
You'll have regular hospital visits for check-ups, blood tests, scans, and to discuss how you're feeling and any side effects. You'll also be asked to fill in questionnaires about your quality of life to see how the treatment affects your daily well-being. The exact number of visits and the full duration of your participation will be explained by the study team, but typically these kinds of studies involve ongoing treatment and follow-up for a significant period.
Potential risks and benefits
Locations (2)
- —Spain
- —Germany
Common questions
What is advanced melanoma?
Advanced melanoma is a serious type of skin cancer that has spread to other parts of the body.
What is Keytruda?
Keytruda is a medicine already used for melanoma that helps your body's immune system fight the cancer.
What does 'untreated' mean in this study?
It means you haven't received any treatment for your advanced melanoma before joining this study.
What is a 'Phase II' clinical study?
Phase II studies are early tests to see how safe and effective a new treatment is for a specific condition.
Will I know which treatment I'm getting?
Because this is a randomised study, you will be assigned to either the combination therapy or Keytruda alone, and you will know which treatment you are receiving.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.